that failed at the cardiovascular level of rats. NYR has already passed all the GLP study results that the cholesterol drug has not. The only reason the stock is trading at a 18 million market cap and should be multiples of where it is today is the cholesterol drug hiccup at GLP. Right now this should be at all time highs on the charts and will get there again as safety progresses and GLP studies are 100 percent completed this coming week or next
The drug on the same settings as first line FDA drugs is already superior just needs to clear safety and that’s in the quarter ahead. Will still become north of 100 million dollars in the period just like its peers that have cleared safety
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)